Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (250)	2/9/1999 10:10:00 PM
From: LLCF	Read Replies (1) \| Respond to of 804

<Hope market will not overreact with other cancer companies> Ahh, but we do hope they overreact! DAK

To: Miljenko Zuanic who wrote (250)	2/9/1999 10:23:00 PM
From: John Bloxom	Read Replies (2) \| Respond to of 804

For the record, BMY didn't pass on endostatin; ENMD wouldn't license it to BMY. BTW, no vested interests here. I owned ENMD before the run and sold every share the day of the run. Never bought it back - have been waiting for evidence that they could make enough angio and endo to start in the clinic. From those over on the ENMD thread, I was hearing that that was going to be very tough to do. Looks like those guys were right. Don't count ENMD out. I hear that endo is a far simpler molecule than angio. Got lots of CELG. Hope it doesn't get hurt too bad in all of this. Regards, John